About this Research Topic
During early years, pharmaceutical companies used to manufacture drugs without much help from academies or other scientists. However, the last 15 years witnessed a flurry of drugs where collaboration took place between academies, clinicians and other scientists, and pharmaceutical companies. The results are astonishing with several drugs that treat multiple sclerosis (MS), cancer, systemic lupus erythematosus (SLE), Crohn’s diseases and other inflammatory bowel diseases (IBD), among others have been approved and their mechanisms of action (MOA) reported. Drugs like Avonex, Copaxone, Tysabri, Gilenya, Tecfidera, among others have been used for treating MS patients. These drugs have immunomodulatory activities ranging from switching the immune system towards a Th2-type response to activating natural killer (NK) cells. On the other hand, drugs such as Sipuleucel-T, Ipilimumab, Alemtuzumab, Cetuximab, Rituximab, Bevacizumab, Ofatumumab, among many others, have been approved for treating many types of cancer. Similar to those drugs approved for MS patients, drugs used to treat cancer patients have immunomodulatory effects. In addition there is a great progress in treating other autoimmune diseases such as IBD and SLE. Topics that will be covered in this issue include, but not restricted to:
1. MOA of drugs for treatment of MS.
2. MOA of drugs for treatment of Cancer.
3. MOA of drugs for treatment of SLE.
4. MOA of drugs for treatment of IBD.
5. MOA for drugs for treatment of other autoimmune diseases.
6. MOA for drugs for treatment of immunodeficient diseases.
1. MOA of drugs for treatment of MS.
2. MOA of drugs for treatment of Cancer.
3. MOA of drugs for treatment of SLE.
4. MOA of drugs for treatment of IBD.
5. MOA for drugs for treatment of other autoimmune diseases.
6. MOA for drugs for treatment of immunodeficient diseases.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
